NCI Natural Product Drug Development To Get New Emphasis; Suggestions Of Critic Accepted
In Brief: Grants To Get Biggest Share Of NCI’s Extra $74 Million; A PR Failure In Pittsburgh
FDA’s New Guideline Proposal Meets More NCI Objections
FDA Holds Up Another IND; Rauscher, FDA Commissioner Hold “Excellent” Meeting
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Trump targets HHS in $810M appropriations clawback
- Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?









